The AAO Journal, 2022/06, 32(2):29. doi: 10.53702/2375-5717-32.2.15, type of study: ,rct,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

Free full text   (https://meridian.allenpress.com/aaoj/article/32/2/15/482674/LBORC-NUFA-Poster-Abstracts-2022-Students)

Keywords:

covid-19 vaccination [1]
antibody response [2]
OMT [3925]
osteopathic manipulative treatment [3946]
randomized controlled trial [947]

Abstract:

Introduction/Background: Multiple studies have shown benefit to treating patients with osteopathic manipulative treatment (OMT) in conjunction with receiving their immunizations. Our group decided to replicate these studies on a larger scale with the COVID-19 vaccines. Objective: We hypothesize that the use of OMT will increase antibody (IgG) responses as quantified by SARSCoV-2 antibody (IgG) against spike protein levels and the duration of antibody titers after mRNA COVID-19 vaccination. We are also tracking medication usage and side effects of vaccines and breakthrough cases. Methods: 91 subjects were randomized into either control groups with vaccine only or intervention group with the vaccines in conjunction with two sessions of OMT after the vaccine was administered and the following day. Participants had blood drawn on: day 0 (1st vaccine), day 7, day 21 (2nd vaccine), and days 28, 35, 90, 182, and 365. Blood samples were processed and bio-banked for future antibody testing. Results: We have successfully recruited and retained 91 participants, of which there is a diverse representation. Our retention rate is 87.5% over the course of 7 months. Reported symptoms and medication usage after each of the vaccines has been very similar between the two groups, yet of those 12 subjects who have experienced breakthrough cases, self-reported symptom severity, length of symptoms, and days of medication usage have been higher in the control group than in intervention group. Discussion/Conclusion: We have successfully recruited and retained 91 participants and continue this ongoing study. OMT has shown promise in dampening the effects of the breakthrough cases to date. The first set of serum samples is soon to be processed for levels of SARSCoV-2 antibody (IgG) against spike protein and results are forthcoming.